Retrospective Study on the Safety and Efficacy of Clopidogrel in the Treatment of Acute Cerebral Infarction
International Journal of Neurologic Physical Therapy
Volume 4, Issue 1, March 2018, Pages: 24-28
Received: Apr. 6, 2018; Accepted: Apr. 23, 2018; Published: May 17, 2018
Views 732      Downloads 58
Authors
Xiufeng Xin, Department of Neurology and Stroke Center, The First Affiliated Hospital of Jinan University, Institute of Clinical Neuroscience, Guangzhou, China
Anding Xu, Department of Neurology and Stroke Center, The First Affiliated Hospital of Jinan University, Institute of Clinical Neuroscience, Guangzhou, China
Wanyong Yang, Department of Neurology and Stroke Center, The First Affiliated Hospital of Jinan University, Institute of Clinical Neuroscience, Guangzhou, China
Zefeng Tan, Department of Neurology and Stroke Center, The First Affiliated Hospital of Jinan University, Institute of Clinical Neuroscience, Guangzhou, China
Article Tools
Follow on us
Abstract
Till now there’s no large sample, randomized and double-blinded research of clopidogrel in acute cerebral infarction. There have been some studies of combined and loading dosage of clopidogrel for antiplatelet treatment but the NIHSS is no more than 5 potints. Our study is to evaluate the efficacy and safety of clopidogrel in acute ischemic stroke. It’s a single center retrospective study. Collect information of patients with acute ischemic stroke from January 1st 2012 to May 31st 2015, using of different antiplatelet drugs, occuring of progressive ischemic stroke, risk factors of cardiovascular and cerebrovascular diseases, etiological classification of cerebral infarction, NIHSS scores on admission and 7 days after admission were collected and was calssified into different groups (NIHSS≤3, 4-7, 8-15 and >15 potints). correlation statistical analysis was performed with chi-square test. A total of 1008 patients were collected, 94 of them had progressive ischemic stroke. There was no significant difference between aspirin group and clopidogrel group (routine clopidogrel group and loading clopidogrel group) within 7 days of onset. Clopidogrel group was superior to aspirin in reducing early recurrence and deterioration within 24 hours while NIHSS on admission was greater than 3 points. PIS has close relation to admission time after onset and severity of clinc. There was no significant difference in the incidence of safety events between aspirin and clopidogrel (routine clopidogrel and loading clopidogrel). Loading dosage of clopidogrel is as safe as the routine group and aspirin group.
Keywords
Acute Cerebral Infarction, Clopidogrel, Progressive Ischemic Stroke, Cerebral Infarction Hemorrhage Transformation
To cite this article
Xiufeng Xin, Anding Xu, Wanyong Yang, Zefeng Tan, Retrospective Study on the Safety and Efficacy of Clopidogrel in the Treatment of Acute Cerebral Infarction, International Journal of Neurologic Physical Therapy. Vol. 4, No. 1, 2018, pp. 24-28. doi: 10.11648/j.ijnpt.20180401.14
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet (London, England) 1997; 349: 1641-9.
[2]
The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet (London, England) 1997; 349: 1569-81.
[3]
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet (London, England) 1996; 348: 1329-39.
[4]
Seadon S, Lang E. Clopidogrel with aspirin versus aspirin alone in prevention of stroke following transient ischemic attack or acute minor stroke. Cjem 2015; 17: 315-7.
[5]
Derdeyn CP, Chimowitz MI, Lynn MJ et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet (London, England) 2014; 383: 333-41.
[6]
Johnston SC, Amarenco P. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. The New England journal of medicine 2016; 375: 1395.
[7]
Zhao Y, Yang W, Tan Z et al. Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial. Stroke and vascular neurology 2017; 2: 118-23.
[8]
Meyer DM, Albright KC, Allison TA, Grotta JC. LOAD: a pilot study of the safety of loading of aspirin and clopidogrel in acute ischemic stroke and transient ischemic attack. Journal of stroke and cerebrovascular diseases: the official journal of National Stroke Association 2008; 17: 26-9.
[9]
Wang Y, Pan Y, Zhao X et al. Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes. Circulation 2015; 132: 40-6.
[10]
Chinese Medical Association Neurology Society and Chinese Medical Association Neurology Branch of Cerebrovascular Disease. Guidelines for the diagnosis and treatment of Acute Ischemic Stroke in China 2014. Chinese Journal of Neurology 2015; 4: 246-257.
[11]
Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-13.
[12]
Leung LY, Albright KC, Boehme AK et al. Short-term bleeding events observed with clopidogrel loading in acute ischemic stroke patients. Journal of stroke and cerebrovascular diseases: the official journal of National Stroke Association 2013; 22: 1184-9.
[13]
Birschel P, Ellul J, Barer D. Progressing stroke: towards an internationally agreed definition. Cerebrovascular diseases (Basel, Switzerland) 2004; 17: 242-52.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186